206 related articles for article (PubMed ID: 37121712)
21. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.
Mauro MJ; Hughes TP; Kim DW; Rea D; Cortes JE; Hochhaus A; Sasaki K; Breccia M; Talpaz M; Ottmann O; Minami H; Goh YT; DeAngelo DJ; Heinrich MC; Gómez-García de Soria V; le Coutre P; Mahon FX; Janssen JJWM; Deininger M; Shanmuganathan N; Geyer MB; Cacciatore S; Polydoros F; Agrawal N; Hoch M; Lang F
Leukemia; 2023 May; 37(5):1048-1059. PubMed ID: 36949155
[TBL] [Abstract][Full Text] [Related]
22. Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.
Yeung DT; Shanmuganathan N; Hughes TP
Blood; 2022 Jun; 139(24):3474-3479. PubMed ID: 35468180
[TBL] [Abstract][Full Text] [Related]
23. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
Schoepfer J; Jahnke W; Berellini G; Buonamici S; Cotesta S; Cowan-Jacob SW; Dodd S; Drueckes P; Fabbro D; Gabriel T; Groell JM; Grotzfeld RM; Hassan AQ; Henry C; Iyer V; Jones D; Lombardo F; Loo A; Manley PW; Pellé X; Rummel G; Salem B; Warmuth M; Wylie AA; Zoller T; Marzinzik AL; Furet P
J Med Chem; 2018 Sep; 61(18):8120-8135. PubMed ID: 30137981
[TBL] [Abstract][Full Text] [Related]
24. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q; Li Z; Qin Y; Li W; Xu N; Liu B; Zhang Y; Meng L; Zhu H; Du X; Chen S; Liang Y; Hu Y; Liu X; Song Y; Men L; Chen Z; Niu Q; Wang H; Lu M; Yang D; Zhai Y; Huang X
J Hematol Oncol; 2022 Aug; 15(1):113. PubMed ID: 35982483
[TBL] [Abstract][Full Text] [Related]
25. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
Wylie AA; Schoepfer J; Jahnke W; Cowan-Jacob SW; Loo A; Furet P; Marzinzik AL; Pelle X; Donovan J; Zhu W; Buonamici S; Hassan AQ; Lombardo F; Iyer V; Palmer M; Berellini G; Dodd S; Thohan S; Bitter H; Branford S; Ross DM; Hughes TP; Petruzzelli L; Vanasse KG; Warmuth M; Hofmann F; Keen NJ; Sellers WR
Nature; 2017 Mar; 543(7647):733-737. PubMed ID: 28329763
[TBL] [Abstract][Full Text] [Related]
26. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
[TBL] [Abstract][Full Text] [Related]
27. Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib.
Häselbarth L; Karow A; Mentz K; Böttcher M; Roche-Lancaster O; Krumbholz M; Jitschin R; Mougiakakos D; Metzler M
Cancer Immunol Immunother; 2023 Jun; 72(6):1661-1672. PubMed ID: 36602564
[TBL] [Abstract][Full Text] [Related]
28. Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.
Li YF; Combes FP; Hoch M; Lorenzo S; Sy SKB; Ho YY
Clin Pharmacokinet; 2022 Oct; 61(10):1393-1403. PubMed ID: 35764773
[TBL] [Abstract][Full Text] [Related]
29. Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study.
Minami Y; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Dawson MK; Matsumura I
Int J Hematol; 2024 Jun; ():. PubMed ID: 38888812
[TBL] [Abstract][Full Text] [Related]
30. Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase.
Choi EJ
Blood Res; 2023 Apr; 58(S1):S29-S36. PubMed ID: 36891575
[TBL] [Abstract][Full Text] [Related]
31. Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review.
Kumar V; Singh P; Gupta SK; Ali V; Verma M
Mol Cell Biochem; 2022 Apr; 477(4):1261-1279. PubMed ID: 35129779
[TBL] [Abstract][Full Text] [Related]
32. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
[No Abstract] [Full Text] [Related]
33. Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells.
Okabe S; Gotoh A
BMC Cancer; 2023 Sep; 23(1):827. PubMed ID: 37670241
[TBL] [Abstract][Full Text] [Related]
34. [Recent Advance of Newly Therapy for Chronic Myeloid Leukemia with
Lai HR; Wu QM; Yang YZ; Li J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1579-1583. PubMed ID: 37846720
[No Abstract] [Full Text] [Related]
35. Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib.
Oruganti B; Lindahl E; Yang J; Amiri W; Rahimullah R; Friedman R
J Biol Chem; 2022 Aug; 298(8):102238. PubMed ID: 35809644
[TBL] [Abstract][Full Text] [Related]
36. Novel therapeutic approaches in chronic myeloid leukemia.
Özgür Yurttaş N; Eşkazan AE
Leuk Res; 2020 Apr; 91():106337. PubMed ID: 32200189
[TBL] [Abstract][Full Text] [Related]
37. Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?
Padala S; Cortes J
Haematologica; 2023 Nov; 108(11):2913-2918. PubMed ID: 37102603
[TBL] [Abstract][Full Text] [Related]
38. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
[TBL] [Abstract][Full Text] [Related]
39. High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation.
Uchida Y; Koyama D; Manabe K; Suzuki K; Asano N; Endo M; Fukatsu M; Sano T; Hayashi K; Takano M; Takahashi H; Kimura S; Ikezoe T
Intern Med; 2024 Mar; 63(5):717-720. PubMed ID: 37407456
[TBL] [Abstract][Full Text] [Related]
40. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
